An interventional study of Active tDCS and individualized language training in Primary Progressive Aphasia, sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli. Completed at 4 sites in Italy. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary Progressive Aphasia (PPA) is a syndrome due to different neurodegenerative disorders selectively disrupting language functions. PPA specialist care is underdeveloped. There are very few specialists (neurologists, psychiatrists, neuropsychologists and speech therapists) and few hospitals- or community-based services dedicated to diagnosis and continuing care. Currently, healthcare systems struggle to provide adequate coverage of diagnostic services, and care is too often fragmented, uncoordinated, and unresponsive to the needs of people with PPA and their families. Recently attention has been gained by digital-health technologies, such immunoassay analyzer and high-field MRI, the most promising approaches to increase our understanding of neurodegeneration, and by new non-invasive brain stimulation techniques such as transcranial direct current stimulation (tDCS) that allow a personalized treatment approach. Our goal is to develop a new treatment approach in PPA in which the regional secondary care centers participating in this project should be the hub of a regional network. The MAINSTREAM (WP2- Efficacy of personalized training in the early stage of PPA) looks forward to introduce and evaluate therapeutic innovation such as tDCS coupled with language therapy in rehabilitation settings (WP2 Early Treatment).
This objective will be pursued by conducting a randomized controlled pilot study in order to evaluate the efficacy of a combined treatment of Active (anodal) tDCS and individualized language training compared to Placebo tDCS combined with individualized language training in a subgroup of mild PPA defined using the Progressive Aphasia Severity Scale (PASS) (Sapolsky D, Domoto-Reilly K, Dickerson BCJA. Use of the Progressive Aphasia Severity Scale (PASS) in Monitoring Speech and Language Status in PPA. (2014) 28(8-9):993-1003).
60 patients with PPA will be recruited from IRCCS Istituto Centro San Giovanni di Dio, Fatebenefratelli, Brescia; IRCCS Fondazione Istituto Neurologico Nazionale C. Mondino, Pavia; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan and Fondazione Don Carlo Gnocchi - ONLUS, Milan.
The diagnostic evaluation will include cognitive and language testing, neurologic examination and neuroimaging (Magnetic Resonance Imaging (MRI) or Positron Emission Tomography PET)).
All the patients will undergo five consecutive days a week for two weeks of treatment sessions of 25 minutes:
The two groups will be matched for sex, age, education, language severity (as defined in the Frontotemporal Dementia Clinical Dementia Rating subscale), and overall severity according to the FTD Clinical Dementia Rating.
Two trained neuropsychologists will administer the neuropsychological testing at baseline (T0), post-treatment (T1) and 3-months (T2) follow-up. All of assessments will be conducted by the same assessor.
To elucidate the mechanisms underlying tDCS effects, Magnetic Resonance Imaging (MRI) and bimolecular data will be collected at T0 and T1 (after the treatment).
77 studies on the registry are indexed under Aphasia, Primary Progressive; 28 are open to participants now.
This study's enrollment of 70 is above the median of 30 across 60 interventional studies indexed under Aphasia, Primary Progressive.
Browse Aphasia, Primary Progressive studies →IRCCS Centro San Giovanni di Dio Fatebenefratelli is the lead sponsor of 36 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The group will receive five consecutive days a week for two weeks of 25 minutes sessions of Active tDCS combined with an individualized language training
Device: Active tDCS · Behavioral: individualized language training
The group will receive five consecutive days a week for two weeks of 25 minutes sessions of Placebo tDCS combined with an individualized language training
Behavioral: individualized language training · Device: Placebo tDCS
Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);
individualized language training
Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);
Change in measure of naming as assessed by International Picture Naming Project Task (IPNP)
International Picture Naming Project Task (IPNP): trained (score range: min= 0, max= 32, higher score=better outcome) and untrained object items (score range: min= 0, max= 32, higher score=better outcome); action items (score range: min= 0, max= 60, higher score=better outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of quality of life as assessed by Stroke and Aphasia Quality of Life Scale - 39 (SAQoL-39)
Stroke and Aphasia Quality of Life Scale - 39 (SAQoL-39) is a measure of health-related quality of life in people with long-term aphasia. It provides a total score from 1 to 5 (higher score=better outcome) and it analyzes the following four domains: physical (score range: min= 1, max= 5, higher score=better outcome); psychosocial (score range: min= 1, max= 5, higher score=better outcome); communication (score range: min= 1, max= 5, higher score=better outcome) and energy (score range: min= 1, max= 5, higher score=better outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of quality of life as assessed by Communication Outcome After Stroke (COAST)
Communication Outcome After Stroke (COAST) is a measure of the functional communication in daily activities and of the impact of the quality of life point of view of aphasia patient (COAST total score range: min= 0, max= 80, higher score=better outcome) and their carer (Carer COAST total score range: min= 0, max= 80, higher score=better outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of quality of life as assessed by Functional Outcome Questionnaire-aphasia
Functional Outcome Questionnaire-aphasia is a measure of aphasia's functional and pragmatic communication in home and community settings, It provides a total score from 32 to 160 (higher score=better outcome) and it is divided into four subscales: communicating basic needs (CBN score range: min= 1, max= 35, higher score=better outcome); making routine requests (MRR score range: min= 1, max= 35, higher score=better outcome); communicating new information (CNI score range: min= 1, max= 40, higher score=better outcome) and attention/other communication skills (AO score range: min= 1, max= 50, higher score=better outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in dementia severity as assessed by Frontotemporal Dementia- Clinical Dementia Rating Scale (FTD-CDR)- Sum of Boxes
Frontotemporal Dementia- Clinical Dementia Rating Scale (FTD-CDR)- Sum of Boxes (score range: min= 0, max= 24, higher score=worse outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in dementia severity as assessed by Global Clinical Dementia Rating (CDR) plus NACC FTLD
Global Clinical Dementia Rating (CDR) plus NACC FTLD (score range: min= 0, max= 3, higher score=worse outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in aphasia severity as assessed by Progressive Aphasia Severity Scale (PASS)
PASS is a measure of severity and progression of language deficits in patients with PPA. The scale assesses ten linguistic domains (each score range: min= 0, max= 3): articulation (higher score=worse outcome), fluency (higher score=worse outcome), syntax and grammar (higher score=worse outcome), word retrieval and expression (higher score=worse outcome), repetition (higher score=worse outcome), auditory comprehension (higher score=worse outcome), single word comprehension (higher score=worse outcome), reading (higher score=worse outcome), writing (higher score=worse outcome) and functional communication (higher score=worse outcome). Moreover, it analyzes three supplemental domains (each score range: min= 0, max= 3): initiation of conversation (higher score=worse outcome), turn taking during conversation (higher score=worse outcome) and generation of language (higher score=worse outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in functional communication skills as assessed by Lincoln Speech Questionnaire
Lincoln Speech Questionnaire provides a speech score (score range: min= 0, max= 14, higher score=better outcome) and an understanding score (score range: min= 0, max= 5, higher score=better outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in aphasia severity as assessed by Communication Severity Rating Scale (Goodglass and Kaplan)
Communication Severity Rating Scale (Goodglass and Kaplan): score range: min= 0, max= 5, higher score=better outcome.
Time frame: Baseline up to 2 weeks and 3 months
Change in depressive symptoms as assessed by Beck Depression Inventory (BDI)
Beck Depression Inventory (BDI): score range: min= 0, max= 63, higher score=worse outcome
Time frame: Baseline up to 2 weeks and 3 months
Change in behavior and personality as assessed by Frontal Behavioral Inventory (FBI)
Frontal Behavioral Inventory (FBI): score range: min= 0, max= 72, higher score=worse outcome.
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of naming as assessed by Picture Naming subtest from Screening for Aphasia in NeuroDegeneration (SAND)
Picture Naming subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 14, higher score=better outcome), living score (score range: min= 0, max= 7, higher score=better outcome) and non-living score (score range: min= 0, max= 7, higher score=better outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of comprehension as assessed by Auditory sentence comprehension subtest from Screening for Aphasia in NeuroDegeneration (SAND)
Auditory sentence comprehension subtest from Screening for Aphasia in NeuroDegeneration (SAND): total score range: min= 0, max= 8, higher score=better outcome.
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of comprehension as assessed by Single-word comprehension subtest from Screening for Aphasia in NeuroDegeneration (SAND)
Single-word comprehension subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 12, higher score=better outcome), living score (score range: min= 0, max= 6, higher score=better outcome) and non-living score (score range: min= 0, max= 6, higher score=better outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of repetition as assessed by Repetition subtest from Screening for Aphasia in NeuroDegeneration (SAND)
Repetition subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 10, higher score=better outcome), words score (score range: min= 0, max= 6, higher score=better outcome) and non-words score (score range: min= 0, max= 4, higher score=better outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of repetition as assessed by Sentence repetition subtest from Screening for Aphasia in NeuroDegeneration (SAND)
Sentence repetition subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 6, higher score=better outcome), predictable sentences score (score range: min= 0, max= 3, higher score=better outcome) and unpredictable sentences score (score range: min= 0, max= 3, higher score=better outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of reading as assessed by Reading subtest from Screening for Aphasia in NeuroDegeneration (SAND)
Reading subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 16, higher score=better outcome), words score (score range: min= 0, max= 12, higher score=better outcome) and non-words score (score range: min= 0, max= 4, higher score=better outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of writing as assessed by Writing subtest from Screening for Aphasia in NeuroDegeneration (SAND)
Writing subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides Information Units score (score range: min= 0, max= 6, higher score=better outcome), total number of words score (score range: min= 0, max= no limits, higher score=better outcome), number of nouns/total number of words score (score range: min= 0, max= 1, higher score=better outcome), number of verbs/total number of words (score range: min= 0, max= 1, higher score=better outcome), number of correct syntactic structures/total number of syntactic structures score (score range: min= 0, max= 1, higher score=better outcome), number of orthographic errors score (score range: min= 0, max= no limits, higher score=worse outcome), number of lexico-semantic errors/number of words score (score range: min= 0, max= 1, higher score=worse outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of semantics as assessed by Semantic association subtest from Screening for Aphasia in NeuroDegeneration (SAND)
Semantic association subtest from Screening for Aphasia in NeuroDegeneration (SAND): total score range: min= 0, max= 4, higher score=better outcome.
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of oral production as assessed by Picture description subtest from Screening for Aphasia in NeuroDegeneration (SAND)
Picture description subtest from SAND provides Information Units score (score range: min= 0, max= 8, higher score=better outcome), total number of words score (score range: min= 0, max= no limits, higher score=better outcome), number of nouns/total number of words score (score range: min= 0, max= 1, higher score=better outcome), number of verbs/total number of words score (score range: min= 0, max= 1, higher score=better outcome), number of sentences score (score range: min= 0, max= no limits, higher score=better outcome), number of subordinates/number of sentences score (score range: min= 0, max= no limits, higher score=better outcome), number of repaired sequences/number of words score (score range: min= 0, max= 1, higher score=worse outcome), number of phonological errors/number of words (score range: min= 0, max= 1, higher score=worse outcome), number of lexico-semantic errors/number of words (score range: min= 0, max= 1, higher score=worse outcome).
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of naming as assessed by Subtest from Aachener Aphasie Test (AAT)
Naming subtest from Aachener Aphasie Test (AAT): score range: min= 0, max= 120, higher score=better outcome.
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of object naming as assessed by Subtest from Battery for the Assessment of Aphasic Disorders (BADA)
Subtest from Battery for the Assessment of Aphasic Disorders (BADA): score range: min= 0, max= 30, higher score=better outcome.
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of fluency abilities as assessed by Verbal Fluency (semantic and phonemic)
Verbal Fluency (semantic and phonemic): score range min= 0, max= no limits, higher score=better outcome.
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of constructional praxia as assessed by Rey-Osterrieth Complex Figure-Copy
Rey-Osterrieth Complex Figure-Copy: score range min= 0, max= 36, higher score=better outcome.
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of verbal long-term memory as assessed by Story Recall
Story Recall: score range min= 0, max= 28, higher score=better outcome.
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of nonverbal long-term memory as assessed by Rey-Osterrieth Complex Figure-Recall
Rey-Osterrieth Complex Figure-Recall: score range min= 0, max= 36, higher score=better outcome.
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of attentional abilities as assessed by Trial Making Test
Trial Making Test: score range: min= n/a, max= no limits, higher score=worse outcome.
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of executive abilities as assessed by Stroop Test
Stroop Test: score range: min= n/a, max= no limits, higher score=worse outcome.
Time frame: Baseline up to 2 weeks and 3 months
Change in measure of global cognitive impairment as assessed by Mini Mental State Examination (MMSE)
Mini Mental State Examination (MMSE): score range: min= 0, max= 30, higher score=better outcome.
Time frame: Baseline up to 2 weeks and 3 months
Change in molecular biomarkers as assessed by the size and the concentration of plasma Extracellular vesicles (EVs)
Size and the concentration of plasma EVs
Time frame: Baseline up to 2 weeks
Change in molecular biomarkers as assessed by Neurofilament light chain (NFL) levels
Neurofilament light chain (NFL) levels
Time frame: Baseline up to 2 weeks
Change in molecular biomarkers as assessed by Glial Fibrillary Acidic Protein (GFAP) levels
Glial Fibrillary Acidic Protein (GFAP) levels
Time frame: Baseline up to 2 weeks
Change in molecular biomarkers as assessed by brain-derived neurotrophic factor (BDNF)
Brain-derived neurotrophic factor (BDNF) levels
Time frame: Baseline up to 2 weeks
Change in molecular biomarkers as assessed by neurogranin levels
Neurogranin levels
Time frame: Baseline up to 2 weeks
Change in functional connectivity as derived from resting-state functional MRI
Functional connectivity as derived from resting-state functional MRI
Time frame: Baseline up to 2 weeks
Change in structural connectivity as derived from diffusion-weighted MRI
Structural connectivity as derived from diffusion-weighted MRI
Time frame: Baseline up to 2 weeks
Ran from Feb 2023 to primary completion in Jan 2026, 35 months.
Of 38 non-industry interventional studies with no phase under Aphasia, Primary Progressive, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 59. This study's 35 months is below that.
Counting every sponsor, half of 38 studies reached it within 40 months; a quarter within 26 and three quarters within 59.
Completion moved once since we started tracking on Sep 25, 2026: Feb 2026 → Jan 2026, on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aphasia, Primary Progressive →
IRCCS Centro San Giovanni di Dio Fatebenefratelli